glp-1 pfizer Pfizer's Push into GLP‑1 Drugs Signals a New Era in Obesity Treatment — and a The challenge of developing oral
Description
October 19, 2021
Ellis PR, Kendall CWC, Ren Y, et al

Therefore, if a new oral drug in development is intended to be co-administered with a GLP-1 agonist, we highly recommend conducting a healthy volunteer drug-drug interaction prior to Phase 3 trials to characterize the impact on the PK of the candidate new drug

doi: 10.1016/s0028-3908(97)00038-5

You pay separately for labs, medications, supplements, and imaging
